Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.55 |
| ▸ | CTSK | P43235 | 6/20 | 0.54 |
| ▸ | SLC6A9 | P48067 | 10/20 | 0.52 |
| ▸ | CTSV | O60911 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244597 | 0.92 | CTSS (0.55) | CTSSCTSKSLC6A9CTSVCTSL | |
| SCHEMBL3904027 | 0.87 | CTSS (0.56) | CTSSCTSKSLC6A9CTSVCTSL | |
| SCHEMBL3239756 | 0.85 | CTSS (0.48) | CTSSCTSKSLC6A9CTSVCTSL | |
| SCHEMBL3243956 | 0.82 | SLC6A9 (0.58) | CTSSCTSKSLC6A9CTSVCTSL | |
| SCHEMBL3238355 | 0.81 | SLC6A9 (0.42) | SLC6A9 | |
| SCHEMBL3238600 | 0.79 | UTS2R (0.46) | CTSSCTSVCTSL | |
| SCHEMBL3238677 | 0.79 | SLC6A9 (0.62) | CTSSCTSKSLC6A9P2RX7 | |
| SCHEMBL3234846 | 0.78 | SLC6A9 (0.61) | CTSSCTSKSLC6A9P2RX7 | |
| SCHEMBL3231177 | 0.77 | KLRK1 (0.41) | — | |
| SCHEMBL13970179 | 0.76 | CTSS (0.53) | CTSSCTSKSLC6A9CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | CTSS 2250/4885CTSK 2569/4885SLC6A9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.